Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 47

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 47
---
 In the event that our licensees fail to do so, our trademark rights
could be diluted. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition,
results of operations and prospects.

Patent terms may not be sufficient to effectively protect our products and business for an adequate period of time.

Patents have a limited lifespan.
In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date.
Although various extensions may be available, the term of a patent, and the protection it affords, is limited. Even if patents covering
our technologies and their uses are obtained, once the patent has expired, we may be open to competition. In addition, although upon issuance
in the United States a patent’s term can be extended based on certain delays caused by the USPTO, this extension can be reduced
or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for
the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after
such products are commercialized. If we do not have sufficient patent terms to protect our products, technologies and their uses, our
business would be seriously harmed.

Our patent portfolio See
“Business—Intellectual Property—GelrinC”) has expiration dates between 2025 and 2036. While we have
attempted to develop a patent portfolio that includes pending patent applications covering subsequent improvements in our products
and processes, we cannot be sure if these patent applications will result in any issued patents. Accordingly, we are not currently
able to assess to what extent the expiration of the basic patents will expose us to competition. If we are not able to implement
subsequent sufficient patents to protect our products, technologies and their uses, we may not be able to stop a competitor from
marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our
business.

<div align='center'>32</div>

Changes in U.S. patent laws may limit our ability to obtain, defend and/or enforce our patents.

Patent reform legislation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents. The Leahy-Smith America Invents Act, or the Leahy-Smith Act, includes a number of significant changes to U.S. patent law.
These include provisions that affect the way patent